By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Amivantamab > Amivantamab Dosage
Miscellaneous antineoplastics
https://themeditary.com/dosage-information/amivantamab-dosage-10686.html

Amivantamab Dosage

Drug Detail:Amivantamab (Amivantamab [ am-ee-van-ti-mab ])

Drug Class: Miscellaneous antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Non-Small Cell Lung Cancer

Weeks 1 to 4:

  • Less than 80 kg: 1050 mg IV once a week for 4 doses
  • At least 80 kg: 1400 mg IV once a week for 4 doses

Week 5 onwards:
  • Less than 80 kg: 1050 mg IV every 2 weeks
  • At least 80 kg: 1400 mg IV every 2 weeks

Duration of therapy: Until disease progression or unacceptable toxicity

Infusion Rates for 1050 mg Dose:
  • Week 1 (split dose infusion):
  • Day 1 (350 mg dose):
  • Initial rate: 50 mL/hour
  • Subsequent rate: 75 mL/hour
  • Day 2 (700 mg dose):
  • Initial rate: 50 mL/hour
  • Subsequent rate: 75 mL/hour
  • Week 2 (1050 mg dose): 85 mL/hour
  • Subsequent weeks (1050 mg dose): 125 mL/hour

Infusion Rates for 1400 mg Dose:
  • Week 1 (split dose infusion):
  • Day 1 (350 mg dose):
  • Initial rate: 50 mL/hour
  • Subsequent rate: 75 mL/hour
  • Day 2 (1050 mg dose):
  • Initial rate: 35 mL/hour
  • Subsequent rate: 50 mL/hour
  • Week 2 (1400 mg dose): 65 mL/hour
  • Week 3 (1400 mg dose): 85 mL/hour
  • Subsequent weeks (1400 mg dose): 125 mL/hour

Comments:
  • The dose should be based on baseline body weight; dose adjustments are not needed for subsequent body weight changes.
  • The initial dose should be administered as a split infusion in Week 1, on Day 1 and Day 2.
  • Before the initial infusion on Week 1 (Days 1 and 2), premedication should be administered to reduce the risk of infusion-related reactions.
  • An antihistamine and antipyretic should be administered before all infusions.
  • A glucocorticoid is required for Week 1 (Days 1 and 2) doses only and should be used as needed for subsequent infusions.
  • The initial infusion rate may be increased to the subsequent infusion rate after 2 hours without an infusion-related reaction.

Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by US FDA-approved test, whose disease has progressed on/after platinum-based chemotherapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Dose reductions for adverse reactions:

  • Less than 80 kg:
  • First dose reduction: 700 mg
  • Second dose reduction: 350 mg
  • Third dose modification: This drug should be discontinued.
  • At least 80 kg:
  • First dose reduction: 1050 mg
  • Second dose reduction: 700 mg
  • Third dose modification: This drug should be discontinued.

Dermatologic Adverse Reactions (including acneiform dermatitis, pruritus, dry skin):
  • Grade 2: Supportive care management should be started. Reactions should be reassessed after 2 weeks; if rash does not improve, dose reduction should be considered.
  • Grade 3: This drug should be withheld and supportive care management should be started. Upon recovery to Grade 2 or less, this drug should resume at a reduced dose; if no improvement within 2 weeks, this drug should be permanently discontinued.
  • Grade 4 and severe bullous, blistering, or exfoliating skin conditions (including toxic epidermal necrolysis): This drug should be permanently discontinued.

Infusion-Related Reactions:
  • Grade 1 to 2: The infusion should be interrupted if infusion-related reaction is suspected; the patient should be monitored until reaction symptoms resolve. The infusion should resume at 50% of the infusion rate at which the reaction occurred; if there are no additional symptoms after 30 minutes, the infusion rate may be increased according to the recommended infusion rate. A corticosteroid should be included with premedications for the next dose.
  • Grade 3: The infusion should be interrupted and supportive care agents should be administered; the patient should be monitored until reaction symptoms resolve. The infusion should resume at 50% of the infusion rate at which the reaction occurred; if there are no additional symptoms after 30 minutes, the infusion rate may be increased according to the recommended infusion rate. A corticosteroid should be included with premedications for the next dose.
  • Recurrent Grade 3 or Grade 4: This drug should be permanently discontinued.

Interstitial Lung Disease (ILD)/Pneumonitis:
  • Any Grade: This drug should be withheld if ILD/pneumonitis is suspected; this drug should be permanently discontinued if ILD/pneumonitis is confirmed.

Other Adverse Reactions:
  • Grade 3: This drug should be withheld until recovery to Grade 1 or less or baseline. If recovery occurs within 7 days, this drug should resume at the same dose; if recovery occurs after 7 days (but within 4 weeks), this drug should resume at a reduced dose. If recovery does not occur within 4 weeks, this drug should be permanently discontinued.
  • Grade 4: This drug should be withheld until recovery to Grade 1 or less or baseline. If recovery occurs within 4 weeks, this drug should resume at a reduced dose; this drug should be permanently discontinued if recovery does not occur within 4 weeks or for recurrent Grade 4 reactions.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Select patients for treatment based on the presence of EGFR exon 20 insertion mutations; for information on US FDA-approved tests: http://www.fda.gov/CompanionDiagnostics
  • Administer premedication to reduce the risk of infusion-related reactions; premedications include:
  • Antihistamine (diphenhydramine [25 to 50 mg] or equivalent): Administer 15 to 30 minutes (IV) or 30 to 60 minutes (oral) before administration of this drug; required at all doses.
  • Antipyretic (acetaminophen [650 to 1000 mg]): Administer 15 to 30 minutes (IV) or 30 to 60 minutes (oral) before administration of this drug; required at all doses.
  • Glucocorticoid (dexamethasone [10 mg] or methylprednisolone [40 mg] or equivalent): Administer IV 45 to 60 minutes before administration of this drug; required at initial dose (Week 1, Days 1 and 2) but optional for subsequent doses.
  • Administer the diluted solution by IV infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, nonpyrogenic, low protein-binding polyethersulfone (PES) filter (pore size: 0.2 micrometer) primed with diluent only.
  • Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), polyvinylchloride (PVC), polypropylene (PP), or polyethylene (PE).
  • Due to the high incidence of infusion-related reactions during initial therapy, infuse this drug via a peripheral line for Weeks 1 and 2; infusions may be administered via central line for subsequent weeks.
  • Do not infuse this drug concomitantly in the same IV line with other agents.

Storage requirements:
  • Unopened vials: Store in a refrigerator at 2C to 8C (36F to 46F) in original carton to protect from light; do not freeze.
  • Diluted solutions: Administer within 10 hours (including infusion time) at room temperature 15C to 25C (59F to 77F).

Reconstitution/preparation techniques:
  • This drug should be diluted and prepared for IV infusion before administration; infusion bags must be made of PVC, PP, PE, or polyolefin blend (PP+PE).
  • The initial infusion should be prepared as close to administration time as possible to allow for a possibly extended infusion time in case of an infusion-related reaction.
  • The manufacturer product information should be consulted.

IV compatibility:
  • Compatible: 5% dextrose solution, 0.9% sodium chloride solution

General:
  • This indication was approved under accelerated approval based on overall response rate and duration of response; continued approval may depend on verification and description of clinical benefit in confirmatory trials.

Monitoring:
  • General: For any signs/symptoms of infusion reactions (during infusion)
  • Respiratory: For new/worsening symptoms indicative of ILD/pneumonitis (during therapy)

Patient advice:
  • Read the US FDA-approved patient labeling (Patient Information).
  • Notify health care provider immediately if any signs/symptoms of infusion-related reactions occur.
  • Contact health care provider immediately for new/worsening respiratory symptoms.
  • Limit direct sun exposure during therapy and for 2 months after the last dose; use broad-spectrum ultraviolet A (UVA)/ultraviolet B (UVB) sunscreen and wear protective clothing during therapy. Apply alcohol-free emollient cream to dry skin.
  • Contact ophthalmologist if eye symptoms develop; contact lenses should be discontinued until symptoms are evaluated.
  • Contact health care provider for signs/symptoms of paronychia.
  • Patients of childbearing potential: Use effective contraception during therapy and for 3 months after the last dose; notify health care provider of a known/suspected pregnancy.
  • Do not breastfeed during therapy and for 3 months after the last dose.

Frequently asked questions

  • How does Rybrevant work?
  • How is Rybrevant administered?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by